Clinical Utility of Antipeptidyl Arginine Deiminase Type 4 Antibodies

Darrah, Erika; Martinez-Prat, Laura; Mähler, Michael

doi:10.3899/jrheum.180905

Cited by 8 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The advent of new diagnostic platforms combined with deep learning artificial intelligence constitutes a new frontier in aPL testing that holds the promise of closing serological gaps in autoantibody diagnostics. This has been demonstrated by recent studies showing the potential clinical utility of this profiling approach in rheumatoid arthritis an idiopathic inflammatory myopathy [8][9][10][11].…”

Section: New Frontiers In Apl Testing: the Panel Approachmentioning

confidence: 85%

Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome

Sciascia

Radin

Ramírez

et al. 2020

Autoimmunity Reviews

Self Cite

View full text Add to dashboard Cite

Patients with antiphospholipid syndrome (APS) present with clinical features of recurrent thrombosis and pregnancy morbidity and persistently test positive for the presence of antiphospholipid antibodies (aPL). At least one clinical (vascular thrombosis or pregnancy morbidity) and one lab-based (positive test result for lupus anticoagulant, anticardiolipin antibodies and/or anti-β2-glycoprotein 1 antibodies) criterion have to be met for a patient to be classified as having APS. Nevertheless, the clinical variety of APS encompasses additional signs and symptoms, potentially affecting any organ, that cannot be explained exclusively by a prothrombotic state. Those manifestations, also known as extra-criteria manifestations, include haematologic (thrombocytopenia and haemolytic anaemia), neurologic (chorea, myelitis and migraine) manifestations as well as the presence of livedo reticularis, nephropathy and valvular heart disease. The growing body of evidence describing the clinical aspect of the syndrome has been paralleled over the years by emerging research interest focusing on the development of novel biomarkers that might improve the diagnostic accuracy for APS when compared to the current aPL tests. This review will focus on the clinical utility of extra-criteria aPL specificities.Besides, the promising role of a new technology using particle based multi-analyte testing that supports aPL panel algorithm testing will be discussed. Diagnostic approaches to difficult cases, including real-world case studies investigatingthe diagnostic added value of extra criteria aPL, particularly anti-phosphatidylserine/prothrombin,will also be examined.

show abstract

Section: New Frontiers In Apl Testing: the Panel Approachmentioning

confidence: 85%

Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome

Sciascia

Radin

Ramírez

et al. 2020

Autoimmunity Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consequently, novel markers that help to stratify patients based on disease phenotypes are important to further improve the prognosis prediction and management of RA. Anti-PAD4 IgG has been reported to be associated with ACPA and a more severe disease course in several independent studies [ 7 , 9 , 13 ]. Anti-PAD4 IgG has also been demonstrated to be present in ACPA negative individuals [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, variable associations of these antibodies with measures of inflammation, disease activity, or erosion have been repeatedly reported, indicating the clinical value of anti-PAD4 antibodies as prognostic biomarkers that could help stratify patients based on the severity of the disease. Furthermore, associations between anti-PAD4 IgG and ACPA [ 7 ], disease severity [ 9 , 10 , 13 ], worse baseline radiographic joint damage [ 7 ], and a better response to treatment escalation [ 14 ] have also been reported.…”

Section: Introductionmentioning

confidence: 99%

Anti-Protein-Arginine Deiminase 4 IgG and IgA Delineate Severe Rheumatoid Arthritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

There is a strong need for biomarkers of rheumatoid arthritis (RA) in all phases of the patient’s journey and to enable the implementation of precision medicine strategies to improve patient care. The objective of this study was to evaluate the presence of anti-protein-arginine deiminase (PAD) 4 IgG and IgA in the sera of RA patients and disease controls, and to investigate their association with joint erosion and biological treatment use. Sera from 104 RA and 155 controls were tested for the presence of anti-PAD4 IgG and IgA using a new particle-based multi-analyte technology (PMAT). Information on the erosive disease and biological treatment use was available for 54 of the RA patients, who were also tested for anti-citrullinated protein antibodies (ACPA). An association between the autoantibodies and these clinical features was investigated. Anti-PAD4 showed sensitivity and specificity values of 25.0% and 94.2% for IgG and of 21.2% and 94.8% for IgA for RA, respectively. The levels of these antibodies were also significantly higher in RA patients vs. controls, in erosive RA vs. non-erosive disease, and in patients under biologics vs. patients that were not on this treatment regimen. The anti-PAD4 IgG and IgA levels were correlated (rho = 0.60, p < 0.0001), but individuals that were positive for only one of the two isotypes were also observed. Anti-PAD4 IgG and IgA are associated with severe RA, and they represent valuable biomarkers for prognosis prediction and patient stratification.

show abstract

“…Следует подчеркнуть, что, как и другие аутоантитела, анти-ПАД4 могут выявляться до клинической манифестации РА. При этом чаще серопозитивны по анти-ПАД4 пациенты с «развернутым» РА (29-35%), чем с «ранним» (16-18%) [50,51,52]; анти-ПАД4 чаще обнаруживаются у АЦЦП-позитивных, чем у АЦЦП-негативных пациентов [53,54]. Однако, по данным L. Martinez-Pra и соавт.…”

Section: антитела к пептидил-аргининдезаминазе (анти-пад)unclassified

New laboratory biomarkers of rheumatoid arthritis

Dibrov¹

2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The review presents data on new biomarkers for the diagnosis of rheumatoid arthritis, considers the diagnostic parameters of antibodies to carbamylated proteins, antibodies to peptidyl arginine deaminase, antibodies to homocysteinylated α1-antitrypsin, 14-3-3η, macrophage soluble scavenger receptor A. The use of new biomarkers can improve the diagnosis of RA in the early stages, as well as stratify patients based on the prognosis of the disease and provide a rational selection of therapy.

show abstract

Clinical Utility of Antipeptidyl Arginine Deiminase Type 4 Antibodies

Cited by 8 publications

References 9 publications

Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome

Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome

Anti-Protein-Arginine Deiminase 4 IgG and IgA Delineate Severe Rheumatoid Arthritis

New laboratory biomarkers of rheumatoid arthritis

Contact Info

Product

Resources

About